CEOCFO interviews NomosLogic CEO Matthew Hardy on molecular medicine infrastructure

CEOCFO Magazine has published an interview with NomosLogic Founder and CEO Matthew Hardy about the company’s role as an infrastructure layer for molecular medicine. Hardy said the platform is designed to connect sequencing companies, hospitals, pharma, payers and other stakeholders while delivering deterministic, clinically useful genetic interpretations.

Why it matters: - NomosLogic is positioning itself as infrastructure, not a competitor, in molecular medicine. - The company is targeting a broad set of users, including sequencing companies, hospitals, point-of-care providers, pharmaceutical firms, drug researchers, payers and insurance companies. - Hardy says the goal is to help clinicians make faster and more accurate decisions from molecular data.

What happened: - CEOCFO Magazine announced an interview with NomosLogic Founder and CEO Matthew Hardy on June 24, 2026. - The interview centered on NomosLogic, a molecular medicine infrastructure company based in Midvale, Utah. - CEOCFO described the piece as a look at NomosLogic’s role in defining a category in molecular medicine infrastructure. - More information is available in the full interview.

The details: - Hardy said NomosLogic is “the infrastructure layer for the world of molecular medicine” and compared the company to roads that connect cities. - Hardy said the platform can serve multiple parts of the healthcare and life sciences ecosystem because it connects them together. - Hardy described a personal example in which the system identified a CFTR variant linked to his gastrointestinal issues and anemia. - Hardy said that information led doctors to perform scopes, find polyps they would not have found otherwise, and treat him more appropriately. - Hardy said NomosLogic is deterministic, meaning the same data produces the same result every time. - Hardy said the system returns yes, no, or unknown, and uses a no-call when evidence is insufficient. - Hardy said a yes result means the answer is 100% certain, rather than probabilistic.

Between the lines: - The interview frames NomosLogic as an enabling layer for molecular medicine rather than a point solution. - The deterministic positioning is meant to differentiate the platform from machine-learning systems that may produce probabilistic outputs. - Hardy is also making a clinical safety argument, linking no-call results and certainty thresholds to fewer wrong findings and lower liability risk for doctors.

What's next: - NomosLogic is likely to keep pitching its platform as connective tissue across diagnostics, care delivery, research and reimbursement. - The company’s category-building strategy appears focused on winning adoption by being useful to many parts of the healthcare stack at once. - CEOCFO’s interview gives NomosLogic a public forum to expand that message to investors and industry readers.